GeneDx Holdings Return on Equity

GeneDx Holdings (SMFR) currently reports a ROE of -43.55%. That is below the Healthcare sector average of 21.67%. Use the charts on this page to explore GeneDx Holdings's ROE history and peer comparisons.

GeneDx Holdings's ROE of -43.55% is lower than the Healthcare sector average of 21.67%. That is roughly 301.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but GeneDx Holdings's current -43.55% should be judged against Healthcare norms (sector average: 21.67%) and against SMFR's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -43.55%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.67%. From there, open related valuation or income-statement pages for GeneDx Holdings, and consider following SMFR for alerts when major investors trade the stock.

GeneDx Holdings is classified in the Healthcare sector. On ROE, it currently shows -43.55% versus a sector average near 21.67%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SMFR with unrelated industries.